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Selective trihydroxyazepane NagZ inhibitors increase
sensitivity of Pseudomonas aeruginosa to b-lactams†
Martine Mondon,a Soo Hur,b Grishma Vadlamani,c Prerana Rodrigues,c
Polina Tsybina,b Antonio Oliver,d Brian L. Mark,c David J. Vocadlo*b and
Yves Blériot*a
AmpC b-lactamase confers resistance to b-lactam antibiotics in many
Gram negative bacteria. Inducible expression of AmpC requires an
N-acetylglucosaminidase termed NagZ. Here we describe the synthesis
and characterization of hydroxyazepane inhibitors of NagZ.
We find that these inhibitors enhance the susceptibility of clinically
relevant Pseudomonas aeruginosa to b-lactams.
Resistance to frontline b-lactams in Gram negative bacteria is a
growing clinical problem.1 Given the prevalence of bacterial
pathogens that harbour either inducible chromosomal AmpC
or inducible plasmid-borne AmpC,2–5 new strategies to sup-
press this resistance mechanism are needed.
Inducible AmpC expression is regulated by peptidoglycan meta-
bolites produced within the bacterium.6 The presence of b-lactams
leads to increased cytosolic levels of the metabolite GlcNAc-1,6-
anhydroMurNAcpeptide, which is cleaved by a conserved enzyme of
the Gram-negative peptidoglycan cell wall recycling pathway termed
NagZ (Fig. 1).7 NagZ removes the non-reducing GlcNAc residue to
liberate 1,6-anhydroMurNAc peptides, which induce transcription
of AmpC b-lactamase to confer resistance to the b-lactam anti-
biotic.7 b-Lactam therapy also frequently selects for mutations
that cause hyperproduction of AmpC. One approach that is
being explored to reverse resistance to b-lactams is to generate
inhibitors of NagZ that can act to hinder the production of
AmpC by disrupting its induction pathway.8–10 One challenge
facing this approach is that NagZ inhibitors can also inhibit
functionally related human enzymes.
NagZ enzymes belong to the GH3 family of the glycoside
hydrolases.11 Detailed kinetic12,13 and X-ray structural studies8,14,15
of NagZ enzymes have revealed that they use a two step mechanism
involving the formation and breakdown of a covalent glycosyl-
enzyme intermediate. The 2-acetamido group of the GlcNAc residue
of the substrate plays no role in catalysis, which is in contrast to
human b-acetylglucosaminidases from GH2013,16 and GH84,17,18
which use a catalytic mechanism in which the 2-acetamido group
of the substrate acts as a nucleophile to yield a bicyclic oxazoline
intermediate. b-Hexosaminidase A (HexA) and b-hexosaminidase B
(HexB) are GH20 enzymes and their dysfunction gives rise to
heritable lysosomal storage diseases. The GH84 enzyme known as
O-GlcNAcase (OGA) removes O-linked b-N-acetylglucosamine residues
(O-GlcNAc) from serine and threonine residues of nucleocytoplasmic
proteins.19,20 Examination of the active sites of the GH3, GH20, and
GH84 enzymes reveals that the active site topology interacting with
the 2-acetamido group of the substrate differs.21 For GH20 and GH84
enzymes, this pocket envelops the acetamido group, whereas for the
NagZ enzymes this substituent rests against the surface of the enzyme
and is solvent exposed. Exploiting this discrepancy by incorporating
N-acyl substituents of various volumes therefore offers a tractable
route to generating selective inhibitors of NagZ.
Several different glycosidase inhibitors that can inhibit diverse
exo-N-acetyl-b-glucosaminidases, including various enzymes from
GH3, GH20, and GH84, have been reported. Among the most
potent of these inhibitors are PUGNAc,22 the iminosugar-based
AcDNJ,8,10 and the glycosylimidazoles.23 An additional class that
has gained attention over the last two decades is the family of
polyhydroxylated azepanes.24–28
Fig. 1 NagZ substrate, product (GlcNAc), PUGNAc, and azepane 1. The stem
peptide is not shown for reasons of clarity.
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When protonated, the basic nitrogen of azepanes is thought to
confer resemblance to the oxocarbenium ion-like transition state
proposed for NagZ and other glycoside hydrolases. The azepanes
also display increased conformational flexibility compared to the six-
membered iminosugar inhibitors.29 This increased plasticity enables
these molecules to be accommodated within the active sites of
glycoside hydrolases, as illustrated by the (3S,4R,5R,6S)-3-acetamido-
4,5,6-trihydroxyazepane 1, that mimics GlcNAc and inhibits eukar-
yotic GH20 and GH84 enzymes with Ki values ranging from 0.4 mM
to 11 mM.26 The versatility of the azepane scaffold prompted us to
explore the potential of various (3S,4R,5R,6S)-3-N-acyl-4,5,6-trihydrox-
yazepanes as inhibitors of NagZ.
We find that azepane 1 is a good inhibitor of NagZ but shows
poor selectivity (Table 1). To gain insight into the molecular basis of
NagZ inhibition by azepane 1 we determined the X-ray crystal
structure of this molecule bound to NagZ from the opportunistic
human pathogen Burkholderia cenocepacia (BcNagZ). The complex
was solved by molecular replacement using a model of BcNagZ
(PDB 4GNV) from which ligands and solvents were removed. Like
other NagZ enzymes BcNagZ is a single-domain enzyme containing
a (b/a)8 barrel fold (TIM barrel) (Fig. S1, ESI†). The structure of this
enzyme in complex with 1 reveals several hydrogen-bonding inter-
actions with the enzyme that contribute to the potency of this
molecule as an inhibitor of GH3 NagZ enzymes (Fig. 2A).
In particular, the catalytic nucleophile of BcNagZ, Asp253, forms
a 2.7 Å hydrogen-bond with the endocyclic nitrogen (N1) of 1—an
interaction that cannot occur between the nucleophile and GlcNAc,
(Fig. 2B) suggesting this interaction of 1 underlies its potency
against NagZ. The structures also reveal significant space
surrounding the endocyclic nitrogen as well as the acetyl group.
Based on these structures, and the structures of GH84 OGA homo-
logues as well as GH20 human hexosaminidase, we envisioned that
selectivity toward NagZ could be obtained by exploring structural
variations at the acetamido group and through alkylation of the
endocyclic nitrogen. We therefore generated a panel of 3-N-acyl
derivatives of (3S,4R,5R,6S)-3-acetamido-4,5,6-trihydroxyazepane 1
and evaluated these against NagZ, OGA, and HexA.
We modified the route to 130a by using PPh3 on a solid support.
It enabled smooth conversion of the starting azidolactol into the
corresponding N,O acetal. Its reduction with NaBH3CN followed
by protection of the endocyclic nitrogen as its benzyl carbamate
afforded 3-hydroxyazepane 2 in 45% yield. Activation of the free OH
as its mesylate followed by azide displacement furnished azidoaze-
pane 3 in 75% yield. Reduction with PPh3 followed by acylation of
the resulting crude amine with acyl anhydrides or acyl chlorides
furnished the corresponding 3-N-acyl azepanes 4–8 in 45–74% yield.
Hydrogenolysis yielded target azepanes 1 and 9–12 (Scheme 1).
The azepane inhibitor scaffold was also elaborated by endo-
cyclic N-alkylation. Such modified polyhydroxylated piperidines can
be selective and potent inhibitors of various glycosidases, including
family GH20 b-glucosaminidases.30b We therefore examined
such modifications on the selectivity and potency of azepanes for
these enzymes. Such N-alkylation of azasugars mimics the aglycon
moiety of substrates of these enzymes.31 Here we investigated the
commonly seen n-butyl group and a phenylbutyl group that we
intended to mimic the aglycon phenylcarbamate substituent of
PUGNAc. Azepane 4 was hydrogenolyzed under mild conditions to
selectively remove the Cbz group and N-alkylated using butyl
bromide or phenylbutyl bromide in the presence of K2CO3 to yield
azepanes 13 (80% yield) and 14 (64% yield) respectively. Hydro-
genolysis under acidic conditions furnished the corresponding
trihydroxyazepanes 15 and 16 (Scheme 2).
With this set of compounds in hand we evaluated their
inhibition of NagZ, OGA, and HexA. We find that increasing the
Compound 1 9 10 11 12 15 16
OGA Ki (mM) 0.7 2.2 47 190 NI 22 2.0
NagZ Ki (mM) 0.4 0.4 7.4 27 NI NI NI
HexA Ki (mM) 3.6 NI NI NI NI 51 14
(Ki OGA/Ki NagZ) 1.8 5.5 6.7 7.1 NA NA NA
(Ki HexA/Ki NagZ) 2.1 + + + NA NA NA
NI: no significant inhibition at 500 mM, NA: not applicable, italic
numbers Ki by Dixon analysis, +: estimated to be at least >1000. For
errors on these measurements see Table S2 (ESI).
Fig. 2 Crystal structure of BcNagZ bound to azepane 1. (A) Active site residues
(grey) and 1 (yellow) are drawn as sticks. The NagZ consensus sequence (blue) has
the putative histidine general acid–base in sticks. Hydrogen bonding interactions
are represented by dashed magenta lines. Electron density is an Fo–Fc map
(3.0 rmsd). (B) Superimposition of the BcNagZ–1 complex with that of BcNagZ
bound to GlcNAc (cyan). See Table S1 (ESI†) for crystal and refinement statistics.
Scheme 1 Synthesis of 3-N-acyl azepanes 1 and 9–12.
Scheme 2 Synthesis of N-alkyl azepanes 15 and 16.
Table 1 Inhibition of Salmonella typhimurium NagZ, OGA, and HexA by azepanes 
1 and 9–16
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structure factors for the BcNagZ–azepane complex are available in
the Protein Data Bank (4MSS).
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size of the N-acyl group in the series including 1, 9–11 has a 
modest effect with regard to inhibition of NagZ and OGA in that 
the Ki values increase with the bulk of this N-acyl group by 
approximately 30-fold for NagZ and 200-fold for OGA. Inter-
estingly, branching of the aliphatic group, as in compound 12, 
leads to a loss of inhibition against all these enzymes. As 
previously observed for other inhibitors, increasing the bulk 
of the N-acyl group beyond acetyl leads to a dramatic loss of 
potency against HexA as seen for compound 9, which differs in 
structure from 1 by only one methylene unit.
Because N-alkylation of iminosugars has often resulted in 
significantly enhanced binding to glycoside hydrolases, including 
to OGA, we speculated that N-alkylated azepanes 15 and 16 would 
be more potent than 1 against these enzymes. Surprisingly, 
however, we find that both these compounds abolished inhibition 
against NagZ and impaired binding to OGA by a modest 2–30 fold 
and to HexA by 4–15 fold.
Since some of these azepanes are good inhibitors of NagZ, in 
particular 10, which retained fair potency and now showed some 
(7-fold) selectivity for NagZ over both OGA and Hex, we decided to 
explore their potential to block NagZ in bacteria and attenuate 
inducible AmpC-mediated b-lactam resistance within a relevant 
bacterial model representative of clinically occurring P. aeruginosa. 
Spontaneous inactivation of dacB, which encodes the non-essential 
penicillin-binding protein 4 (PBP4), is the most common cause 
of AmpC hyper-production and high-level b-lactam antibiotic 
resistance in P. aeruginosa.32 We therefore tested whether 1 or 
10 could potentiate the efficacy of the b-lactam ceftazidime 
against a dacB null mutant of P. aeruginosa (Table S3, ESI†). 
Neither 1 nor 10 had any effect on bacterial growth on their 
own. However, use of 1 mM 1 halved the minimum inhibitory 
concentration (MIC) of P. aeruginosa DdacB from 24 mg ml1 
ceftazidime in the absence of the inhibitor to 12 mg ml1. 
Azepane 10 led to a greater 3-fold reduction in MIC to 8 mg ml1, 
despite this derivative being 18-fold less potent in vitro relative to 
azepane 1, suggesting that its uptake or diffusion into the cells 
must occur more easily. Notably, this value meets the susceptibility 
breakpoint of the Clinical and Laboratory Standards Institute 
(CLSI) for ceftazidime.
The synthetic accessibility of polyhydroxy azepanes, their 
stability and their ability to suppress b-lactam resistance in the 
clinically relevant P. aeruginosa dacB null mutant suggest that these 
compounds could prove useful. The availability of a NagZ–azepane 
complex will facilitate the design of improved NagZ azepane inhi-
bitors. Finally, the recent observation that inactivation of NagZ 
also blocks the emergence of mutations giving rise to b-lactam 
resistance33 makes NagZ an enzyme of high interest; its inhibition 
should not only block antibiotic resistance but could also hinder 
development of mutations  leading to  b-lactam resistance.
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